Companies › Altesa Biosciences
1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vapendavir VP1 capsid protein inhibitor | ERVCC | Phase 2 | Rhinovirus Infection | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07610395 | Vapendavir | Phase 2 | Rhinovirus Infection | Infectious disease | Nov 2027 |
| NCT07610395 | Vapendavir | Phase 2 | Rhinovirus Infection | Infectious disease | Nov 2027 |
–
Vasomune Therapeutics Eagle Pharmaceuticals Code Pharma Peptilogics AVVA Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.